After almost two decades of stagnation, two new drugs for Alzheimer’s have hit the market in the last three years. The approval of Biogen…
The FDA rejected Eli Lilly’s request to expedite the approval process for experimental Alzheimer’s drug donanemab, but the drug’s Phase 3 trial is carrying…
Clinical trials are recruiting younger, healthier participants for Alzheimer’s studies like the new TRAILBLAZER 3 donanemab clinical trial. Alzheimer’s is a notoriously difficult disease…
Can Roche’s investigational anti-amyloid drug, gantenerumab, help slow down or even prevent Alzheimer’s disease? Trials are underway. The amyloid hypothesis—the idea that Alzheimer’s is…
In Being Patient’s LiveTalk series, Dr. David Weidman, associate medical director for research at the Banner Alzheimer’s Institute, shares insights on Eli Lilly’s investigational Alzheimer’s…
The FDA will hasten the review of two more new Alzheimer’s drug candidates, Eli Lilly & Co.’s donanemab and Biogen and Eisai’s lecanemab. Today,…
We talked with Banner Alzheimer’s Institute Director Pierre Tariot about the most recent results from Eli Lilly’s Alzheimer’s trial for donanemab — what he…
This weekend, new batch of data from the TRAILBLAZER-ALZ trial for Eli Lilly’s Alzheimer’s drug donanemab was released, upholding the treatment’s ability to affect…